Nicotinamide treatment

Phase 3Small molecule

AAssistance Publique - Hôpitaux de Paris

Nicotinamide treatment is one of 106 small molecule programs targeting Septic Shock. It is currently in Phase 3.

Indications

Total Trials

Active Trials

105

Competitors

Pipeline

Status by Indication[3][1]

Indication

Septic ShockActive, not recruiting

Acute Kidney InjuryActive, not recruiting

NeuropathyActive, not recruiting

Septic ShockPhase 3

Active, not recruiting

Acute Kidney InjuryPhase 3

Active, not recruiting

NeuropathyPhase 1

Active, not recruiting

Competition

Competitive Landscape

224 competitors in Septic Shock

#DrugCompanyPhaseTrials

Nicotinamide treatment

AAssistance Publique - Hôpitaux de Paris

Phase 3

1 2

Primaxin

Pfizer

Preclinical

2 3

Intropin

Pfizer

Preclinical

2 4

Zyvox

Pfizer

Preclinical

1 5

Doribax

Shionogi

Preclinical

—6

Cubicin

BBaxter Healthcare Corporation

Preclinical

1 7

Glucophage

EMD Serono

Preclinical

1 8

Lipitor

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

1 9

Avastin

BBio-Thera Solutions

Preclinical

1 10

Ultiva

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2028

Phase 1Not yet recruiting

Neuropathy

NCT07258667

Clinical

Trials by Indication[1]

Neuropathy1 trial

Pilot Study of the Efficacy of Nicotinamide (Vitamin B3) in Leber's Hereditary Optic Neuropathy

Not yet recruiting·UUniversity Hospital, Angers·Phase 1·NCT07258667·13 enrolled

Septic Shock1 trial

Does High-dose Vitamin B3 Supplementation Prevent Major Adverse Kidney Events During Septic Shock?

Active, not recruiting·—·Phase 3·NCT04589546·310 enrolled

Acute Kidney Injury1 trial

Graft Acute Kidney Injury: Vitamin B3 to Facilitate Renal Recovery In the Early Life of a Transplant

Completed·AAssistance Publique - Hôpitaux de Paris·Phase 3·NCT05513807·204 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Nicotinamide treatment. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Nicotinamide treatment compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Nicotinamide treatment. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Assistance Publique - Hôpitaux de Paris company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: AAssistance Publique - Hôpitaux de Paris

Nicotinamide treatment

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2028

Trials by Indication[1]

Neuropathy1 trial

Septic Shock1 trial

Acute Kidney Injury1 trial

References

Drug Info

Quick Facts

Related News